Perth, Western Australia, 22 July 2019: Proteolytics Pty Ltd, a clinical-stage biotechnology company developing novel therapeutics for advanced wound care and skin disorders, today announced that an evaluation of the Company’s botanical pawpaw extract (OPAL-A) for the treatment of children with skin disorders has been successful.
Proteolytics Announces First Data from Treatment of Skin Irritation with OPAL-A Pawpaw Extract
Proteolytics Announces First Data from Treatment of Horses with OPAL-A
12 July 2019
Proteolytics Announces In-Vivo Study to Treat Chronic Wounds with OPAL-A Pawpaw Extract
02 August 2019